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Background. Despite substantial interest in biomarkers, their impact on clinical outcomes and variation with
bacterial strain has rarely been explored using integrated databases.
Methods. From September 2006 to May 2011, strains isolated from Clostridium difﬁcile toxin enzyme immuno-
assay (EIA)–positive fecal samples from Oxfordshire, United Kingdom (approximately 600 000 people) underwent
multilocus sequence typing. Fourteen-day mortality and levels of 15 baseline biomarkers were compared between
consecutive C. difﬁcile infections (CDIs) from different clades/sequence types (STs) and EIA-negative controls
using Cox and normal regression adjusted for demographic/clinical factors.
Results. Fourteen-day mortality was 13% in 2222 adults with 2745 EIA-positive samples (median, 78 years) vs 5%
in 20 722 adults with 27 550 EIA-negative samples (median, 74 years) (absolute attributable mortality, 7.7%; 95% CI,
6.4%–9.0%). Mortality was highest in clade 5 CDIs (25% [16 of 63]; polymerase chain reaction (PCR) ribotype 078/ST
11), then clade 2 (20% [111 of 560]; 99% PCR ribotype 027/ST 1) versus clade 1 (12% [137 of 1168]; adjusted
P < .0001). Within clade 1, 14-day mortality was only 4% (3 of 84) in ST 44 (PCR ribotype 015) (adjusted P = .05 vs
other clade 1). Mean baseline neutrophil counts also varied signiﬁcantly by genotype: 12.4, 11.6, and 9.5 × 109 neutro-
phils/L for clades 5, 2 and 1, respectively, vs 7.0 × 109 neutrophils/L in EIA-negative controls (P < .0001) and 7.9 × 109
neutrophils/L in ST 44 (P = .08). There were strong associations between C. difﬁcile-type-speciﬁc effects on mortality
and neutrophil/white cell counts (rho = 0.48), C-reactive-protein (rho = 0.43), eosinophil counts (rho =−0.45), and
serum albumin (rho =−0.47). Biomarkers predicted 30%–40% of clade-speciﬁc mortality differences.
Conclusions. C. difﬁcile genotype predicts mortality, and excess mortality correlates with genotype-speciﬁc
changes in biomarkers, strongly implicating inﬂammatory pathways as a major inﬂuence on poor outcome after CDI.
PCR ribotype 078/ST 11 (clade 5) leads to severe CDI; thus ongoing surveillance remains essential.
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The widespread emergence of hypervirulent polymer-
ase chain reaction (PCR) ribotype 027/NAP1/BI/
sequence type (ST) 1 [1] strains in the early 2000s [2, 3]
substantially increased Clostridium difﬁcile infection
(CDI) incidence. PCR ribotype 027 has also been asso-
ciated with more severe outcomes in most [2, 4, 5] but
not all [6–9] studies. Outcome variation across non-027
strains has rarely been investigated, invariably with
small numbers, although these now account for most
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new CDIs. One study [6] (n = 395) found signiﬁcantly more
complicated disease outcomes with PCR ribotypes 018 (ST 17
from [10]; n = 23) and 056 (ST 34/58 [10]; n = 6), whereas
another [11] (n = 168) reported similar 30-day mortality in
PCR ribotype-027 (n = 46) and 017 (ST 37 [10]; n = 57). Al-
though PCR ribotype 078 (ST 11), common in livestock [12]
and rising in incidence [6, 13], is denoted hypervirulent on the
basis of increased toxin production [14] and individual case se-
verity [15], supporting clinical data are few. Attributable mor-
tality and severe diarrhea was similar in PCR ribotype 078
(n = 54) and 027 (n = 124) in 1 study (both greater than in 501
non-027/078 cases) [13], but PCR ribotype 078 (n = 31) was
not associated with complicated CDI in another [6]. Although
scores to predict CDI severity, complications, or recurrence
have variably included biomarkers (eg, white blood count
[WBC], C-reactive protein [CRP]) [16], no studies have investi-
gated associations between CDI strains and biomarkers.
We aimed therefore to investigate whether the genotype of C.
difﬁcile clinical isolates from multilocus sequence typing (MLST)
was associated with mortality and severity biomarkers using a
large population-based database of CDI cases and to explore as-
sociations between strain-speciﬁc effects on host biomarkers and
mortality to provide insights into infection pathogenesis.
METHODS
Oxford University Hospitals (OUH) NHS Trust provides >90%
of hospital care and all acute services in Oxfordshire (approxi-
mately 600 000 people). It includes 2 large acute teaching hos-
pitals and 1 specialist orthopedic hospital in Oxford and 1
district hospital 35 miles north. The OUH microbiology labora-
tory tests all stool samples from the county, including those
from other healthcare facilities/primary care. From 12 Septem-
ber 2006 to 21 May 2011, all unformed stools submitted for C.
difﬁcile toxin testing, positive by enzyme immunoassay (EIA)
and with sufﬁcient sample remaining, were routinely cultured
and MLST typed [1]. During this period, infection control
policy required all inpatients with diarrhea (≥3 unformed
stools within 24 hours) to have samples sent for EIA testing
and to initiate vancomycin treatment empirically, continuing
for 14 days if CDI was conﬁrmed. Additionally, from May
2007, all unformed samples from those aged ≥65 years were
routinely EIA tested following UK policy.
C. difﬁcile MLST data were anonymously linked to OUH
hospital admissions/discharges, mortality, and laboratory test
results from the Infections in Oxfordshire Research Database
(IORD) through 21 August 2011 [17]. Admissions to other
much smaller regional (including psychiatric/community) hos-
pitals were not included, although samples taken at these loca-
tions were identiﬁable. Rates were calculated using overnight
stays deﬁned by the UK KH03 occupancy statistic. IORD has
Research Ethics Committee (09/H0606/85) and UK National
Information Governance Board (5-07(a)/2009) approval as an
anonymized database without individual informed consent.
The primary outcome was 14-day mortality after EIA-based
CDI detection in adults aged ≥18 years (excluding repeat EIA-
positive cases within 14 days; censoring follow-up at 14 days).
EIA-negative samples were included as controls (excluding
repeat negatives within 14 days and any sample taken after or
within 21 days before the ﬁrst EIA positive). See Supplementary
Material for details.
The primary exposure was type of CDI, categorized by EIA/
culture status or C. difﬁcile phylogenetic clade from MLST [1].
CDI-associated MLST STs correlate reasonably closely with ri-
botype [18] and can be grouped by evolutionary relationships
into clades [10]. These clades persist despite homologous re-
combination and have the same phylogenetic structure with
MLST or whole-genome sequences [19], suggesting they may
behave more similarly in humans. Adjusted mortality risks in
each clade and STs with >20 cases were estimated using Cox
models, with robust variance adjustment for multiple episodes
per patient [20]. EIA-negative controls comprised the reference
category so that risks reﬂected CDI-attributable mortality. In-
dependent predictors were identiﬁed using backward selection
with the Akaike information criterion [21], allowing nonlinear
effects of continuous factors [22]. Exposures considered were
demographics, sample characteristics, previous hospital expo-
sure, and previous healthcare-associated infections (Table 1)
(antibiotic exposure not available). The impact of clade on the
15 biomarkers available for >50% cases within −3 to +1 days of
sample collection was estimated using normal regression on
BoxCox-transformed values. Associations between biomarkers
and 14-day mortality were estimated using Cox models with
multiple imputation (see Supplementary Material).
RESULTS
From September 2006 to May 2011, after 14-day deduplication,
there were 2745 consecutive toxin-EIA-positive stools in 2222
adults (median age, 78 years; interquartile range [IQR], 67–85
years; 2128 (78%) ﬁrst ever EIA-positive) and 27 550 consecu-
tive EIA-negative stools in 20 722 adults without a previous
positive (median age, 74 years; IQR, 63–83 years). Crude
14-day mortality was similar after ﬁrst (13%) vs subsequent
(13%) EIA-positive cases and ﬁrst (5%) vs subsequent (7%)
EIA-negative controls (Figure 1A). Overall attributable mortali-
ty was 7.7% (95% conﬁdence interval [CI], 6.4%–9.0%;
P < .0001; Figure 1A). Fourteen-day mortality was lower after
EIA-positive/culture-negative cases (8%) than after EIA-
positive/culture-positive cases (14%; P < .0001), although still
higher than the 5% in EIA-negative/culture-negative controls
(P = .002).
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Table 1. Characteristics of Clostridium difﬁcile Samples 12 September 2006–21 May 2011 and Relationship With 14-Day Mortality
Number (%) or Median (IQR)
Unadjusted
Univariable Model
Adjusted
Multivariable Modela
Factor
Levels (Effect in
Cox Model)
In EIA Negative
Controls
In EIA Positive
Cases HR (95% CI) P HR (95% CI) P
Type of test EIA negative 27 550 (100%) . . . 1.00 <.0001 1.00 <.0001
EIA positive/culture negative 571 (21%) 1.59 (1.19–2.12) 1.59 (.93–2.73)
EIA positive/not cultured 281 (10%) 2.61 (1.89–3.61) 2.45 (1.62–3.70)
Clade 1 1168 (43%) 2.23 (1.88–2.66) 2.32 (1.71–3.13)
Clade 2 (027/ST 1) 560 (20%) 3.95 (3.26–4.79) 3.40 (2.45–4.68)
Clade 3 (023) 73 (3%) 1.31 (.53–3.26) 1.65 (.62–4.36)
Clade 4 (017/ST 37) 29 (1%) 2.74 (1.04–7.21) 2.65 (.99–7.13)
Clade 5 (078/ST 11) 63 (2%) 5.17 (3.16–8.46) 5.37 (3.10–9.32)
Demographics
Sex Female (vs male) 15 682 (57%) 1566 (57%) 0.79 (.72–.86) <.0001 0.75 (.68–.82) <.0001
Age, years Per 10 years older 74 (63–83) 78 (67–85) 1.42 (1.37–1.47) <.0001 1.41b (1.36–1.47) <.0001
Sample characteristics
Location where sample taken Inpatient 16 598 (60%) 1860 (68%) 1.00 <.0001 1.00 <.0001
Primary care 8108 (29%) 557 (20%) 0.14 (.12–.17) 0.06c (.03–.14)
Outpatient/ER/day case 1395 (5%) 148 (5%) 0.35 (.27–.47) 0.98c (.35–2.78)
Other hospital 1449 (5%) 180 (7%) 0.50 (.40–.63) 0.12c (.05–.30)
If inpatient, speciality Surgical 6112 (37%) 549 (30%) 1.00 <.0001 1.00 <.0001
Medical 10 486 (63%) 1311 (70%) 1.91 (1.71–2.15) 1.64 (1.44–1.88) if EIA−
1.64 (.88–3.06) if EIA +, cult −
0.98 (.73–1.30) if EIA +, cult +
(interaction P= .004)
If inpatient, method Elective 3609 (22%) 363 (20%) 1.00 <.0001 1.00 .01
Emergency 12 989 (78%) 1497 (80%) 1.64 (1.43–1.88) <.0001 1.22 (1.04–1.43)
If inpatient, days
since admitted
Nonlinear effectd 5 (2–12) 9 (2–22) <.0001 <.0001
(Days/10)−1 0.87 (.78–.97) 0.76d (.68–.84)
ln(days/10)a(days/10)−1 1.00 (.95–1.04) 0.90d (.86–.94)
Clinician requested EIA test
when submitting sample
No (mild diarrhea) (vs yes) 7895 (29%) 436 (16%) 0.48 (.42–.54) <.0001 0.69 (.51–.92) .01
Days since last negative
EIA teste
(For every day closer
in the last 2 wk)
. . . 4 (1–8) (if test
in last 2 wk)
0.97e (.95–1.00) .02 0.96 (.94–.99) .007
Previous C. difficile Yes (vs no) 0 (0%) 634 (23%) 0.99e (.78–1.26) .94 (p = 0.18)
Previous hospital exposure
(strictly before the current
admission, if inpatient)
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Table 1 continued.
Number (%) or Median (IQR)
Unadjusted
Univariable Model
Adjusted
Multivariable Modela
Factor
Levels (Effect in
Cox Model)
In EIA Negative
Controls
In EIA Positive
Cases HR (95% CI) P HR (95% CI) P
Ever previously admitted
to OUH
Yes, for ≥1 admission
>8 hours
19 570 (71%) 2253 (82%) 1.00 <.0001 1.00 .01
Yes, but only for <8 hour admissions 2462 (9%) 139 (5%) 0.55 (.45–.68) 0.93 (.71–1.21)
Never 5518 (20%) 353 (13%) 0.63 (.55–.72) 1.30 (1.03–1.63)
Previously admitted to GI ward Yes (vs no) 8484 (31%) 981 (36%) 0.95 (.86–1.05) .34 0.89 (.80–.99) .03
Dialysis/chemotherapy at OUH Yes (vs no) 3051 (11%) 332 (12%) 1.37 (1.21–1.56) <.0001 1.39 (1.21–1.60) <.0001
Number of previous admissions
>8 hours
(per 5 additional >8 hours
admissions)
2 (1–4) 2 (1–5) 1.06f (.99–1.12) .08 0.92 (.84–1.00) .06
Previous hospital stay (hours) (Per doubling of total
previous hours
in hospital)
169 (8–656) 478 (77–1229) 1.11g (1.09–1.13) <.0001 1.02g (.99–1.06) .20
Days since last discharged (Per additional 6 mo
since last OUH
discharge)
285 (42 to >1096) 78 (22–640) 0.92 (.90–.95) <.0001 0.96 (.93–.98) .002
SHEA [35] classification
HO-HCFA 11 628 (42%) 1373 (50%) 1.00 <.0001 (P= .93)
CO-HCFA 3432 (12%) 604 (22%) 0.66 (.57–.76)
Indeterminate 1892 (7%) 248 (9%) 0.54 (.45–.66)
CO 10 598 (38%) 520 (19%) 0.30 (.26–.34)
Abbreviations: CI, confidence interval; CO, community onset; CO-HCFA, community onset–health-care facility associated; cult, culture; EIA, enzyme immunoassay; ER, emergency room; GI, gastrointestinal; HO-
HCFA, hospital onset–health-care facility associated; HR, hazard ratio; IQR, interquartile range; OUH, Oxford University Hospitals; SHEA, Society for Healthcare Epidemiology of America
a HR with opposite effect to unadjusted univariable models due to confounding are underlined. P values in italics show the nonsignificant effects of adding in factors not chosen by the Akaike information criterion
selection.
b Although mortality was lower after tests that had not been directly requested by the clinician, the increase in risk with age was significantly greater following these tests (per 10 years HR = 1.71; 95% CI, 1.48–1.98;
interaction P = .009). For those aged <84.4 years, mortality risks were therefore greater after clinician-requested tests; fore those aged ≥84.4 years, mortality risks were greater after tests that had not originally been
requested by the clinician.
c Mortality reduced even further if EIA test is negative rather than positive (additional HR = 0.63; 95% CI, .43–.94; P = .02).
d Significant nonlinearity, with greatest risk of death on day of admission, then dropping sharply, and then gradually rising.
e Univariable model also adjusts for positive vs negative EIA test.
f Univariable model also adjusts for ever vs never previously admitted.
g Effects significantly (P < .0001) stronger if samples taken in primary care (HR = 1.25; 95% CI, 1.16–1.36 per doubling) or other hospitals (HR = 1.27; 95% CI, 1.16–1.39 per doubling) than as inpatients (HR in table
above) or outpatients/ER/day cases (HR = 0.98; 95% CI, .88–1.10 per doubling; interaction P < .0001).
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In EIA-positive/culture-positive cases, there were substantial
mortality differences between C. difﬁcile clades (P < .0001;
Figure 1A). Fourteen-day mortality was highest in clade 5
(25%; all PCR ribotype 078/ST 11 [10]), then clade 2 (20%;
99% PCR ribotype 027/ST 1), clade 4 (14%; 97% A-B+ PCR ri-
botype 017/ST 37), and clade 1 (12%); lowest mortality
Figure 1. Fourteen-day mortality after enzyme immunoassay (EIA) tests for Clostridium difﬁcile, overall and by strain. A, Fourteen-day mortality by EIA-
negative control vs EIA-positive case and multilocus sequencing type clade if culture positive. B, Fourteen-day mortality by sequence type within clade
1. C, Fourteen-day mortality by age (all tests). Most common ribotypes of isolates from each clade (A) or sequence type (B) shown in brackets. Dashed line
in (B) shows overall clade 1 mortality. Clade 4 not shown in (C) due to small numbers (n = 29). Abbreviations: EIA, enzyme immunoassay.
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occurred in clade 3 (7%; all PCR ribotype 023). The heteroge-
neous clade 1 had 67 STs, 15 with >20 isolates. Observed mor-
tality varied markedly between common clade 1 STs (median,
11%; range, 4%–16%; Figure 1B), although small numbers
limited power to distinguish genuine from chance differences
(exact P = .76). Fourteen-day mortality was only 4% in ST 44
(95% CI, .7%–10%; exact P = .01 vs other clade 1, post hoc test).
Similar relative differences between clades were observed at all
ages (Figure 1C). Over the longer term, mortality was consis-
tently higher in clades 2 and 5 and lower in clades 1 and 3
(Figure 2). In inpatients not dying before 14 days, the median
stay post–EIA test was signiﬁcantly longer in EIA-positive cases
(median, 16; IQR, 7–32) than in EIA-negative controls
(median, 9; IQR, 3–21; P = .0001) and in clade 2 (median, 19;
IQR, 10–34) vs 1 (median, 15; IQR 7–32; P = .005).
Many potential risk factors were strongly associated with 14-
day mortality as expected (Table 1; Supplementary Material).
CDI cases, particularly those from clade 2 (PCR ribotype 027/
ST 1), were older and generally had more of these risk factors.
However, variations in 14-day mortality across C. difﬁcile
clades remained after adjustment (P < .0001; Figure 3). Strong
evidence of higher mortality after clade 5 (PCR ribotype 078)
vs clade 1 CDI (P = .001) and after clade 2 (PCR ribotype 027)
vs clade 1 CDI (P = .002) persisted, with a trend toward higher
mortality with clade 5 vs clade 2 CDI (P = .09). Further, al-
though clades 3 and 5 are genetically similar in several pathoge-
nicity locus genes [10], mortality differed signiﬁcantly between
clade 5 vs clade 3 CDI (P = .03). Within clade 1, adjusted 14-
day mortality risks remained lower in ST 44 (hazard ratio
[HR], 0.31 vs other clade 1; 95% CI, .10–.98; interaction
P = .05). After adjustment, 14-day mortality decreased year-on-
year from 2006 to 2011 in EIA-positive cases (HR per year,
0.88; 95% CI, .80–.96) but not EIA-negative controls (HR, 1.03;
95% CI, .99–1.07; interaction P = .002), with no evidence of dif-
ferential effects in clade 2 (P = .91).
Variation in biomarkers at CDI diagnosis across clades and
associations between excess biomarkers and excess mortality
risks broadly followed three patterns. There was strong evidence
for higher neutrophils/WBC in EIA-positive cases vs EIA-
negative controls and in clades 2, 3, and 5 vs 1 (all P < .01)
(Figure 4A and 4B; Supplementary Table 1). In clade 1–5 CDI
cases, 31%, 46%, 48%, 21%, and 50%, respectively, had WBC >
15 × 109/L (P < .0001) vs 15% in EIA-negative controls. Excess
neutrophils/WBC and excess mortality risks were strongly asso-
ciated across clades (rho = 0.6). However, clade 3 appeared dis-
similar to other clades, with signiﬁcantly higher neutrophil/
WBC vs clade 1, similar to clades 2 (PCR ribotype 027/ST 1)
and 5 (PCR ribotype 078/ST 11), despite signiﬁcantly lower mor-
tality. Variation across clades was similar, but slightly weaker, for
CRP (P = .05) and eosinophils (P = .03; Figure 4C and 4D), with
more severe (higher) CRP and (lower) eosinophils in clades 3
and 5. Associations between excess biomarker and mortality
risks were also weaker (rho = 0.48, −0.35, respectively). At CDI
diagnosis, albumin was signiﬁcantly lower (Figure 4E) and plate-
lets signiﬁcantly higher (Supplementary Figure 1H) in EIA-
positive cases vs EIA-negative controls (P < .0001), but there was
no evidence of clade-speciﬁc differences (P > .50). In clades 1–5,
8%, 7%, 4%, 5%, and 15%, respectively, had albumin < 25 g/dL
(P = .53) vs 5% in EIA-negative controls. However, excess
mortality risks tracked reasonably closely with greater albumin
reductions vs EIA-negative controls, suggesting that greater
patient-level variation may have reduced power.
Figure 2. One-year mortality after ﬁrst-ever Clostridium difﬁcile enzyme immunoassay–positive test or ﬁrst negative before positive test by strain. Abbre-
viation: EIA, enzyme immunoassay.
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Serum sodium was slightly but signiﬁcantly lower in EIA-
positive cases vs EIA-negative controls (P = .006) and in clade 2
(Figure 4F). Although clades 2 and 5 had highest mortality, if
anything, sodium was increased in clade 5 CDI (P = .08 vs
clade 2), leading to no overall association between differences
in sodium and excess mortality risks across the different clades
(rho = 0.02). Hemoglobin was signiﬁcantly lower in EIA-
positive cases vs EIA-negative controls (P < .0001; Figure 4G),
but clade-speciﬁc variation was restricted to higher hemoglobin
in clade 4 (P = .05), with little association with excess mortality
(rho = 0.22). Qualitatively, variation across clades in alanine
aminotransferase (ALT), creatinine, estimated glomerular ﬁltra-
tion rate [23, 24], and serum potassium was similar to hemo-
globin (Supplementary Figure 1, I–L). No clear associations
were evident for urea or alkaline phosphatase (Supplementary
Figure 1N and 1O).
Comparing associations individually for clade 1 STs
(Figure 5) supported the partial surrogacy of differences in neu-
trophils/WBC (rho = 0.48), CRP (rho = 0.43), and eosinophils
(rho = −0.45) for excess mortality risk but suggested a stronger
relationship with albumin (rho =−0.47). Lack of association
for other biomarker changes remained (eg, sodium rho = 0.06;
Figure 5D). ST 44 was an outlier, with signiﬁcantly lower
albumin but similar neutrophils/CRP and mortality risk to
EIA-negative controls.
Lastly, we estimated how much of the variation in C. difﬁcile
clade-associated mortality risk was related to observed bio-
marker differences. As expected given large numbers, all bio-
markers except ALT independently predicted 14-day mortality
in addition to Table 1 factors (Supplementary Table 2).
However, association strength varied substantially, with
albumin, urea, eosinophils, sodium, and CRP most strongly
(and creatinine/estimated glomerular ﬁltration rate most
weakly) related to mortality. Adjusting for baseline bio-
markers explained 41%, 32%, and 37% of the increased mortal-
ity due to clades 1, 2, and 5, respectively (Figure 3). However,
even after adjusting for these biomarker differences across
C. difﬁcile clades (Figure 4), signiﬁcant mortality risk varia-
tion by clade remained (P = .03), with signiﬁcantly higher mor-
tality persisting in clade 2 (PCR ribotype 027) vs clade 1
(P = .01) CDIs.
DISCUSSION
In the largest population-based study of genotype and CDI se-
verity to date, we have exhaustively investigated the relation-
ships between strain types, biomarkers, other risk factors, and
mortality. We have demonstrated unequivocally that PCR ribo-
type 027/NAP1/BI/ST 1 (clade 2) strains have been, and con-
tinue to be, associated with greater attributable mortality. This
Figure 3. Variation in 14-day mortality risks according to Clostridium difﬁcile clade. Abbreviations: adj, adjusted; CI, conﬁdence interval; cult, culture;
EIA, enzyme immunoassay; het, heterogeneity test.
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Figure 4. Variation in 7 biomarkers at diagnosis according to Clostridium difﬁcile clade and association with mortality. A, Neutrophils (×109/L). B, White
cell count (×109/L). C, C-reactive protein (mg/L). D, Eosinophils (×109/L). E, Albumin (g/dL). F, Sodium (mmol/L). G, Hemoglobin (g/dL). For each biomarker,
left-hand panels show mean (95% conﬁdence interval) values at sample collection for enzyme immunoassay (EIA)–negative controls vs EIA-positive cases;
then subdividing EIA-positive cases into culture-negative, not cultured, and culture-positive cases; then subdividing culture-positive cases by clade and
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excess risk persists even after adjusting for large differences in
severity biomarkers. Further, PCR ribotype 078 (clade 5) CDI
has attributable mortality at least as great as PCR ribotype
027/ST 1, in agreement with 1 previous study [13] but in con-
trast with another [6]. Although PCR ribotype 078/clade 5
strains are currently present at low frequency, prospective
Figure 4 continued. comparing sequence type (ST) 44 vs other STs within clade 1; with P values testing for heterogeneity across each group. Means are
calculated on BoxCox-transformed values and back-transformed for presentation (see Supplementary Methods). For each clade and EIA-positive/culture-
negative cases, the right-hand panels plot the standardized adjusted mean difference vs EIA-negative controls from the left-hand panel (on the BoxCox-
transformed scale,±standard error) against the adjusted hazard ratio for mortality vs EIA-negative controls from Table 1. The correlation, ρ, between
biomarker and mortality risk excesses was estimated using multivariable random effects meta-analysis (see Supplementary Methods). Diagonal lines
show the line of best ﬁt (ie, the best prediction of excess mortality for any given excess in biomarkers compared with EIA-negative controls). If differences
in biomarkers across clades completely explained mortality differences (ie, the biomarker was a perfect surrogate for mortality), all the points would lie on
the diagonal line. The closer the points are to the diagonal line, the stronger the relationship between biomarker differences and excess mortality risks.
Points lying far from the diagonal line indicate a mismatch, either high excess mortality with little difference in biomarkers from EIA-negative controls or
vice versa. Abbreviations: CRP, C-reactive protein; cult, culture; EIA, enzyme immunoassay; OUH, Oxford University Hospitals; SE, standard error.
Figure 5. Impact of Clostridium difﬁcile clade and individual sequence type (ST) on biomarkers compared with mortality. A, Neutrophils (×109/L). B, C-re-
active protein (mg/L). C, Albumin (g/dL). D, Sodium (mmol/L). For clades 2–5 (labelled C2, C3, C4, C5) and each clade 1 ST with >20 isolates, the panels
plot the standardized adjusted mean difference vs enzyme immunoassay (EIA)–negative controls (on the BoxCox-transformed scale,±standard error)
against the hazard ratio for mortality vs EIA-negative controls, adjusted as in Table 1. The correlation, ρ, between biomarker and mortality risk excesses
across STs/clades was estimated using multivariable random effects meta-analysis (see Supplementary Methods). Diagonal lines show the line of best ﬁt
(ie, the best prediction of excess mortality for any given excess in biomarkers compared with EIA-negative controls), together with a 95% credibility region
indicated by the shaded region. If a biomarker was a perfect surrogate for mortality (ie, differences in biomarkers across STs/clades completely explained
mortality differences), all the points would lie on the diagonal line. The closer the points are to the diagonal line, the stronger the relationship between bi-
omarker differences and excess mortality risks. Points lying far from the diagonal line indicate a mismatch, either high excess mortality with little diffe-
rence in biomarkers from EIA-negative controls or vice versa. All clade 1 STs lying outside the 95% credibility region on any of the 4 panels are labelled on
each panel; ST 58, which had high mortality in [6], is also labelled. Abbreviations: CRP, C-reactive protein; cult, culture; EIA, enzyme immunoassay; HR,
hazard ratio; SE, standard error; ST, sequence type.
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surveillance demonstrates their continued expansion [25];
ongoing monitoring therefore remains essential.
Comprehensive simultaneous characterization of the impact
of different C. difﬁcile strains on biomarkers and mortality, not
previously described to our knowledge, has enabled us to show
that strain-type-speciﬁc excess mortality risk correlates most
closely with strain-type-speciﬁc changes in inﬂammatory bio-
markers. Conceptually the framework behind these analyses is
similar to that for assessing surrogacy of intermediate for clini-
cal outcomes (eg, blood pressure for cerebrovascular disease)
[26]. Some biomarkers, notably renal-related biomarkers (cre-
atinine, eGFR), were prognostic for mortality but did not vary
signiﬁcantly across CDI cases/controls or clades (ie, were acting
independently of CDI). Others were prognostic and differed
signiﬁcantly between CDI cases and EIA-negative controls but
not across clades. The most prognostic marker, albumin, fell
into this category, possibly because of large variability. Bio-
markers in the most interesting group, particularly neutrophils/
WBC, CRP, and eosinophils, were prognostic and demonstrated
evidence of partial surrogacy (ie, greater differences in baseline
biomarkers between clades translated into greater differences in
14-day mortality). This has 2 consequences: First, quantitative
traits like these biomarkers may provide greater power than
time-to-event outcomes to detect effects of polymorphisms in
genome-wide association studies. Second, surrogate markers in-
dicate causal mechanisms of bacterial pathogenesis and may
identify future therapeutic areas for investigation. Our results
implicate inﬂammatory pathways as the major inﬂuence on
poor outcome after CDI.
Although we found strong associations between strain-
speciﬁc biomarkers and mortality overall, we also discovered
intriguing exceptions that, as exploratory ﬁndings, may indicate
important areas for future investigation. Speciﬁc genotypes
within the large, heterogenous clade 1, notably ST 44, had par-
ticularly low 14-day mortality in post hoc analyses. Although
ST 44 differs by only 1 nucleotide on MLST from ST 10, respec-
tive 14-day mortality was 3% and 11%, the latter typical of
clade 1 overall (12%). However, both STs are consistently iden-
tiﬁed as PCR ribotype 015 [10]. They differ by >1500 single nu-
cleotide polymorphisms across the genome [19] and may also
differ in their accessory genomes, suggesting possible areas for
future study. In contrast, our data suggest ST 49 (PCR ribotype
014) could be a more severe clade 1 genotype; this is an emer-
gent clone in the United Kingdom [25] and should be
monitored closely. Another intriguing ﬁnding is the major dis-
connect between the impact of clade 3 CDI on neutrophils/
WBC/CRP and mortality. Similarities between clades 3 and 5
in severity biomarkers might be expected, as the receptor-
binding domain of their pathogenicity locus tcdB gene (en-
coding one of the major known clostridial toxins) is highly
genetically similar and their tcdC sequences share the same
protein-truncating nucleotide substitution [10]. The latter is
phenotypically equivalent to the single nucleotide deletion in
the clade 2/PCR ribotype 027 tcdC, which causes a protein-
truncating frameshift [10] and possibly leads to hypervirulence
through increased toxin expression [27, 28] (although recent
studies have questioned this [29]). Clades 2, 3, and 5 are also
binary toxin positive [10] (in contrast with clades 1 and 4).
However, the substantially lower mortality in clade 3 vs clade 5
highlights the importance of other, as yet undetermined, viru-
lence or host factors to clinical outcomes [30] and suggests that
increased toxin production alone in PCR ribotype 078 cannot
account for its virulence.
Overall, we found 30%–40% of differences in mortality risk
between strains were due to differences in biomarkers at diagno-
sis. However, in contrast with a recent much smaller study [31],
even after adjusting for biomarker differences (and other fac-
tors) signiﬁcant mortality differences remained across clades;
this suggests that further microbial virulence determinants
remain to be identiﬁed. Of note, the biomarker-adjusted effects
of strain (reported in [31]) adjust away any effect of strain on
outcome mediated through biomarkers, effects that we show to
be substantial (Figure 4).
Our study has some limitations. The EIA assay used for case
ascertainment has suboptimal sensitivity (91.7% in [32]),
similar to other toxin EIAs [32, 33]. However, because of wide-
spread concerns about sensitivity, for most of the study
(through December 2009), multiple diarrheal samples were
submitted from each patient, simultaneously or serially (500–
1100 EIA tests performed monthly), reducing the chance of
completely missing symptomatic CDI. One consequence is that
we almost certainly identiﬁed false positives, perhaps explain-
ing some EIA-positive/culture-negative cases [34]. To reduce
the impact of false negatives, our controls only included EIA-
negative tests >21 days before the ﬁrst EIA positive result.
During the study, there were 9.2 EIA-positive CDIs/10 000
overnight stays in inpatients, compatible with the 3.8–9.5 EIA-
positive CDIs/10 000 overnight stays typical in endemic settings
[35]. Overall, 14-day mortality attributable to EIA-positive CDI
was 7.7%, similar to the 8% in a meta-analysis of 10 975 cases
from 27 studies after 2000 [36] and 11% in another large study
[37], also suggesting generalizability. By necessity, analyses were
limited to available electronic data, which did not include previ-
ous/concomitant antibiotics, speciﬁc comorbid conditions, or
causes of death. Although antibiotics are undoubtedly critical
for developing CDI, given the lack of impact of adjusting for
other important risk factors on strain–mortality associations, it
is plausible that further adjustments would have had little
further effect. Although theoretically C. difﬁcile–related deaths
should provide a more accurate measure of attributable mortali-
ty, practically attributing causes is subjective and usually
unaudited. In contrast, all-cause mortality is objective, and
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differences in early mortality between EIA-positive cases vs
EIA-negative diarrhea controls should be directly or indirectly
CDI related. Although previous studies have considered 30-day
mortality [5], reasonable reinfection rates between 14–30 days
[38] inﬂuenced our prespeciﬁed choice of primary outcome.
However, strain differences were similar at 30 days, and survival
curves were parallel subsequently (Figure 2).
Our study also has important strengths. First is its compre-
hensive scope, including cases from an entire region over
almost 5 years, including 3 hospitals providing acute services
and numerous secondary/primary care providers. Second, it in-
cluded 1893 EIA-positive/culture-positive strain-typed cases,
approximately double the largest previous studies (n = 1008 [5];
n = 715 [13]). Study size becomes increasingly important when
exploring differences between strains; 700–800 cases are
needed to detect an 8% absolute mortality increase (as observed
between clade 1 vs clade 2) with 80% power. Inadequate power
therefore likely explains why smaller studies failed to identify
associations between PCR ribotype 027 and severe outcomes
(eg, n = 123 [7]; n = 128 [39]; n = 236 [40]). We were also able
to compare strains at the clade/ST level, whereas most previous
studies have only compared 027 vs non-027 strains [5], pooling
4 heterogeneous clades. We were unable to conﬁrm previous
reports [6] of poorer outcomes with PCR ribotypes 018 (ST 17
[10]) and 056 (ST 34/58 [10]), although longer-term mortality
was similar in clade 4 (PCR ribotype 017/ST 37) and clade 2
(PCR ribotype 027/ST 1) as previously reported [11]. Our data
conﬁrm that the lack of the large clostridial toxin A (tcdA) in
these clade 4 cases does not lead to less severe outcomes. We
did not ﬁnd any evidence of greater year-on-year mortality re-
ductions in PCR ribotype 027/ST 1 (clade 2) compared with
other clades [39], suggesting overall improvements in outcome
are more likely due to better patient management than strain
effects. The other mortality risk factors we identiﬁed broadly
agree with previous studies [16], mostly reﬂecting disease se-
verity or subsequent management; however, unlike previous
studies, we have adjusted for the potential confounding due to
bacterial type.
In summary, MLST demonstrates that strain predicts mortal-
ity and severity biomarkers at both clade and individual se-
quence-type level. For patient monitoring, neutrophils/WBC,
CRP, and albumin are the key C. difﬁcile–associated biomarkers
that are highly prognostic for short-term mortality and also
partial surrogates (with the possible exception of clade 3). For
surveillance, PCR ribotype 078/ST 11 (clade 5) is associated
with severe CDI, and its prevalence provides an important
context for hospital mortality data [25]. Lastly, our study dem-
onstrates the power from integrating large electronic databases
with molecular sequence-based typing. Using whole-genome
sequencing, approximately 85% of an approximately 4.3-Mb
reference C. difﬁcile genome can be called using standard
mapping [19], providing unparalleled resolution to investigate
severity determinants compared with the 7.4-kb MLST se-
quence used here. Unexpected differences in strains appearing
highly similar by MLST and in biomarker vs mortality relation-
ships hint at the advances that pathogen whole-genome associ-
ation studies will provide in our understanding of bacterial
pathogenesis over the next decade.
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